blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2792746

EP2792746 - OLIGONUCLEOTIDE AND THERAPEUTIC AGENT FOR HYPERLIPIDEMIA CONTAINING SAME AS ACTIVE INGREDIENT [Right-click to bookmark this link]
StatusThe application has been withdrawn
Status updated on  04.12.2015
Database last updated on 15.06.2024
Most recent event   Tooltip04.12.2015Withdrawal of applicationpublished on 06.01.2016  [2016/01]
Applicant(s)For all designated states
National Cerebral and Cardiovascular Center
7-1, Fujishirodai 5-chome
Suita-shi, Osaka 565-8565 / JP
[2014/43]
Inventor(s)01 / OBIKA, Satoshi
c/o OSAKA UNIVERSITY
1-1 Yamadaoka
Suita-shi Osaka 565-0871 / JP
02 / YAMAMOTO, Tsuyoshi
c/o OSAKA UNIVERSITY
1-1 Yamadaoka
Suita-shi Osaka 565-0871 / JP
03 / NAKATANI, Moeka
c/o OSAKA UNIVERSITY
1-1 Yamadaoka
Suita-shi Osaka 565-0871 / JP
04 / SHIBA, Mariko
c/o National Cerebral and Cardiovascular Center
5-7-1 Fujishirodai
Suita-shi Osaka 565-8565 / JP
 [2014/43]
Representative(s)Clements, Andrew Russell Niel, et al
Schlich
9 St Catherine's Road
Littlehampton, West Sussex BN17 5HS / GB
[2014/43]
Application number, filing date12857414.212.12.2012
WO2012JP82255
Priority number, dateJP2011027175112.12.2011         Original published format: JP 2011271751
[2014/43]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013089157
Date:20.06.2013
Language:JA
[2013/25]
Type: A1 Application with search report 
No.:EP2792746
Date:22.10.2014
Language:EN
[2014/43]
Search report(s)International search report - published on:JP20.06.2013
(Supplementary) European search report - dispatched on:EP13.08.2015
ClassificationIPC:C12N15/113, A61K31/712, A61P3/06
[2015/38]
CPC:
C12N15/113 (EP,US); A61P3/06 (EP); C12N2310/11 (EP,US);
C12N2310/315 (EP,US); C12N2310/3231 (EP,US); C12N2310/341 (EP,US)
Former IPC [2014/43]C12N15/113, A61K31/711, A61K48/00, A61P3/06, C07H21/04
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/43]
TitleGerman:OLIGONUKLEOTID UND THERAPEUTIKUM FÜR HYPERLIPIDÄMIE MIT DIESEM ALS WIRKSTOFF[2014/43]
English:OLIGONUCLEOTIDE AND THERAPEUTIC AGENT FOR HYPERLIPIDEMIA CONTAINING SAME AS ACTIVE INGREDIENT[2014/43]
French:OLIGONUCLÉOTIDE ANISI QU'AGENT THÉRAPEUTIQUE POUR L'HYPERLIPIDÉMIE CONTENANT CET OLIGONUCLÉOTIDE EN TANT QUE PRINCIPE ACTIF[2014/43]
Entry into regional phase13.06.2014Translation filed 
13.06.2014National basic fee paid 
13.06.2014Search fee paid 
13.06.2014Designation fee(s) paid 
13.06.2014Examination fee paid 
Examination procedure13.06.2014Examination requested  [2014/43]
27.11.2015Application withdrawn by applicant  [2016/01]
Fees paidRenewal fee
16.12.2014Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]WO2004093783  (ISIS PHARMACEUTICALS INC [US], et al) [X] 1,3-8 * the whole document * [Y] 1-8;
 [XP]WO2012149495  (ISIS PHARMACEUTICALS INC [US], et al) [XP] 1-8 * page 36, line 10 - page 39, line 20 * * page 44, line 25 - page 51, line 9 * * claims 1-57; sequence 3 *;
 [E]WO2013040429  (RANA THERAPEUTICS INC [US], et al) [E] 1,3-7 * the whole document *
 [Y]  - THAZHA P PRAKASH ET AL, "Antisense Oligonucleotides Containing Conformationally Constrained 2??,4??-(N-Methoxy)aminomethylene and 2??,4??-Aminooxymethylene and 2??-O,4??-C-Aminomethylene Bridged Nucleoside Analogues Show Improved Potency in Animal Models", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 53, no. 4, doi:10.1021/JM9013295, ISSN 0022-2623, (20100225), pages 1636 - 1650, (20100128), XP008148699 [Y] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1021/jm9013295
 [YP]  - TSUYOSHI YAMAMOTO ET AL, "Superior Silencing by 2',4'-BNA NC -Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors", JOURNAL OF NUCLEIC ACIDS, (20120926), vol. 269, no. 43, doi:10.1074/jbc.270.6.2620, ISSN 2090-0201, pages 26801 - 7, XP055206711 [YP] 1-8 * the whole document *

DOI:   http://dx.doi.org/10.1155/2012/707323
International search[X]WO2004093783  (ISIS PHARMACEUTICALS INC [US], et al);
 [Y]WO2011052436  (UNIV OSAKA [JP], et al);
 [Y]  - RAHMAN, S. M. A. ET AL., "Design, Synthesis, and Properties of 2',4'-BNANC: A Bridged Nucleic Acid Analogue", J. AM. CHEM. SOC., (2008), vol. 130, pages 4886 - 4896, XP055031784

DOI:   http://dx.doi.org/10.1021/ja710342q
 [YP]  - HIDENORI YASUHARA ET AL., "Ko ApoC-III Antisense Kakusan ni yoru Ko Triglyceride Kessho Chiryoyaku no Kaihatsu", ANTISENSE IDENSHI DELIVERY SYMPOSIUM 2012 YOSHISHU, (20120924), page 51, XP008174952
 [YP]  - YAMAMOTO, T. ET AL., "Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice", MOLECULAR THERAPY NUCLEIC ACIDS, (20120515), vol. 1, page E22, XP055154047

DOI:   http://dx.doi.org/10.1038/mtna.2012.16
by applicantUS7598227
 WO2011052436
    - S. OBIKA ET AL., TETRAHEDRON LETT., (1997), vol. 38, pages 8735 - 8738
    - S. OBIKA ET AL., TETRAHEDRON LETT., (1998), vol. 39, pages 5401 - 5404
    - S. K. SINGH ET AL., CHEM. COMMUN., (1998), vol. 4, pages 455 - 456
    - A. A. KOSHKIN ET AL., TETRAHEDRON, (1998), vol. 54, pages 3607 - 3630
    - S. OBIKA ET AL., BIOORG. MED. CHEM., (2001), vol. 9, pages 1001 - 1011
    - S. M. A. RAHMAN ET AL., ANGEW. CHEM. INT. ED., (2007), vol. 46, pages 4306 - 4309
    - S. M. A. RAHMAN ET AL., NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS, (2007), vol. 26, pages 1625 - 1628
    - K. MIYASHITA ET AL., CHEM. COMMUN., (2007), vol. 36, pages 3765 - 3767
    - S. M. A. RAHMAN ET AL., J. AM. CHEM. SOC., (2008), vol. 130, pages 4886 - 4896
    - M. ZUKER, NUCLEIC ACIDS RES., (2003), vol. 31, pages 3406 - 3415
    - S. F. ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, pages 403 - 410
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.